Fundraising Fox
Azuraophthalmics
Founded 2014 · 11 employees on LinkedIn · 1 known investors
Find your way into Azuraophthalmics
Sign up to see every warm intro you have to Azuraophthalmics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Azuraophthalmics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Azura Ophthalmics develops a new therapeutic class of ophthalmic keratolytics aimed at treating lid margin and ocular surface diseases and other underserved ophthalmic conditions. The company applies drug development expertise to address the core pathophysiology of these eye conditions.
Founders & leadership
L
LubaDirector of Pre-Clinical Development
Investors · 1
OrbiMedlisted by OrbiMedNew York · $1M – $75M
How we know: OrbiMed's portfolio page · the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does Azuraophthalmics do?
- Azura Ophthalmics develops a new therapeutic class of ophthalmic keratolytics aimed at treating lid margin and ocular surface diseases and other underserved ophthalmic conditions. The company applies drug development expertise to address the core pathophysiology of these eye conditions.
- Who are Azuraophthalmics's investors?
- Azuraophthalmics's investors include OrbiMed.